Trillium Therapeutics Inc. (TRIL) News
Filter TRIL News Items
TRIL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TRIL News Highlights
- For TRIL, its 30 day story count is now at 19.
- Over the past 29 days, TRIL's stories per day has been in a clear downtrend, falling by about 0.23 per 2 days.
- The most mentioned tickers in articles about TRIL are LPL, PFE and ACT.
Latest TRIL News From Around the Web
Below are the latest news stories about Trillium Therapeutics Inc that investors may wish to consider to help them evaluate TRIL as an investment opportunity.
Trillium Therapeutics gets Canada, HSR approval for sale to PfizerTrillium Therapeutics (NASDAQ:TRIL) disclosed that applicable waiting periods under the Competition Act in Canada and HSR in the U.S. expired on Monday in regards to its $2.3B sale to Pfizer (NYSE:PFE). The closing of the transaction is expected to occur on or about tomorrow, according to an 8-K filing. Earlier,... |
7 of the Best Stocks to Buy for Their Free Cash FlowThese stocks to buy have a stable business outlook and robust free cash flows. |
Geode Capital Management LLC Acquires 766,327 Shares of Trillium Therapeutics Inc. (NASDAQ:TRIL)Geode Capital Management LLC lifted its holdings in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 1,041.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 839,889 shares of the biotechnology companys stock after acquiring an additional 766,327 shares during [] |
Trillium Therapeutics Inc. (NASDAQ:TRIL) Given Consensus Recommendation of Hold by AnalystsShares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) have been given a consensus rating of Hold by the eight research firms that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers [] |
Trillium Therapeutics Inc. (NASDAQ:TRIL) Shares Purchased by Stifel Financial CorpStifel Financial Corp increased its holdings in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 56.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 81,650 shares of the biotechnology company’s stock after purchasing an additional 29,450 shares during the quarter. Stifel Financial Corp […] |
Trillium Therapeutics Inc. (NASDAQ:TRIL) Shares Sold by Fmr LLCFmr LLC trimmed its position in Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 51.1% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 84,760 shares of the biotechnology company’s stock after selling 88,700 shares during the period. Fmr LLC owned 0.08% of Trillium Therapeutics worth $822,000 at the […] |
LPL Financial LLC Raises Stock Position in Trillium Therapeutics Inc. (NASDAQ:TRIL)LPL Financial LLC lifted its stake in shares of Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) by 2.5% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 244,473 shares of the biotechnology companys stock after acquiring an additional 6,003 shares during the quarter. LPL Financial LLCs holdings in Trillium Therapeutics were worth $2,371,000 as of [] |
Trillium Therapeutics Receives Final Court Order Approving ArrangementCAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Trillium or the Company) (NASDAQ/TSX: TRIL) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the Arrangement) with PF Argentum ULC (PF Argentum), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (Pfizer). |
Trillium Securityholders Approve Acquisition by PfizerCAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (“PF Argentum”) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”) at the special meeting of Trillium securityholders today. Pursuant to the arrangemen |
Is Trillium Therapeutics Inc. (TRIL) A Good Stock To Buy?Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […] |